osteoclastogenesis

BCI hydrochloride ((E)-BCI hydrochloride) is a selective dual-specificity phosphatase 6 (DUSP6) inhibitor that inhibits RANKL-mediated osteoclastogenesis and attenuates oophorectomy-induced bone loss.BCI hydrochloride has anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and partially reverses AE-induced bone loss. BCI hydrochloride has anti-inflammatory activity and can reduce reactive oxygen species (ROS) production, partially reverse AE-induced cytotoxicity, and increase ERK activity, which can be used to study inflammatory diseases.

3-(3-Hydroxyphenyl)propionic Acid (m-Hydroxyphenylpropionic acid) is one of the major metabolites of ingested caffeic acid.it inhibited osteoclastogenesis and bone osteoclastic resorptive activity.

(-)-Gallocatechin gallate ((-)-gallocatechin-3-O-gallate) is the polyphenol isolated from tea, with cancer-preventive activities. (-)-Gallocatechin gallate decreases osteoclastogenesis at 20 microM.

Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.Sciadopitysin shows protective effects on antimycin A-induced toxicity in osteoblastic MC3T3-E1 cells, it may

VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).

(+)-Medicarpin, a pterocarpan, is an isoflavonoid compound derived from medicinal plant species such as Sophora japonica, Zollernia paraensis, Platymiscium yucatamun, Machaerium aristulatum, and Platymiscium floribundum. It potently inhibits osteoclastogenesis and facilitates bone healing and increased bone mass through osteoblast differentiation, mediated by the estrogen receptor (ER) β.

NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity.

Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos NFATc1 pathway. Latanoprost acid can be used in studies about lowering pressure inside the eyes.

Sauristolactam inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation. Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus Chi

S24-14 serves as an effective anti-osteoporosis agent by inhibiting osteoclastogenesis, promoting osteoblast differentiation, and reducing bone resorption.

AS2690168 freebase is an orally active inhibitor of RANKL signaling, capable of suppressing RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

ELP-004 is a TRPC channel inhibitor that blocks Ca2+ entry mediated by TRPC channels. It serves as an osteoclast inhibitor by preventing osteoclast differentiation. ELP-004 also hinders basal Ca2+ levels and the associated translocation of NFATc1 in inflammatory osteoclastogenesis. Additionally, it reduces bone erosion in mouse models of rheumatoid arthritis.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

AS2690168 hydrochloride is an orally active inhibitor of RANKL signaling that can suppress RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

SC 19220 is a prostaglandin E2 receptor EP1 antagonist.SC 19220 inhibits RANKL-induced osteoclastogenesis by inhibiting the RANK RANKL signaling pathway in osteoclast precursors.

Halenaquinone is a phosphatidylinositol 3-kinase inhibitor. Halenaquinone specifically inhibits the secondary DNA binding of RAD51. Halenaquinone inhibits RANKL-induced osteoclastogenesis. Halenaquinone induces apoptosis in PC12 cells.

Kinsenoside ((+)-Kinsenoside) shows significant antihepatotoxic, and anti-inflammatory activities. Kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function, it could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats. Kinsenoside inhibits osteoclastogenesis from macrophages by attenuating RANKL-induced NF-κB and NFATc1 activities, which in turn, prevents bone loss from OVX mice.

2,3-Bis(3-indolylmethyl)indole exhibits a concentration-dependent inhibition of RANKL-induced osteoclastogenesis, actin ring formation, and bone resorption.

Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis.

Mepazine hydrochloride (Pecazine hydrochloride) is a potent MALT1 inhibitor with anticancer and antitumor activities. Mepazine hydrochloride inhibits RANK-induced osteoclastogenesis, suppresses MALT1 activity and tumor growth in pancreatic cancer.

Pexmetinib (ARRY-614) is an orally bioavailable dual p38 MAPK Tie-2 inhibitor studied in acute myeloid leukemia and inhibits osteoclastogenesis and breast cancer-induced osteolysis via the P38 STAT3 signaling pathway.

iso-Dehydrozingerone is a novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice.

1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disorders. 2. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti-oxidative character. 3. Curculigoside possesses potent antioxidant properties against oxidative stress insults. can protect endothelial cells against oxidative injury induced by H2O2, suggesting that this compound may constitute a promising intervention against cardiovascular disorders.

Osteoprotegerin is a soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage.